GHRH Analogs REMS Programs and Special Handling: What Women Need to Know

What Are GHRH Analogs and Why Do They Matter for Women?

GHRH analogs mimic the hypothalamic peptide that signals your pituitary gland to make and release growth hormone (GH). Sermorelin, the class prototype, is a 29-amino-acid fragment of endogenous GHRH. Tesamorelin is a full-length GHRH analog. Both preserve the pulsatile, physiologic pattern of GH secretion, which is important because supraphysiologic continuous GH exposure carries greater metabolic risk.

Women's interest in this class has grown alongside the broader peptide and GLP-1 conversation, particularly in perimenopause and post-menopause, when GH pulse amplitude falls sharply. At the same time, the regulatory picture around compounded GHRH peptides is shifting rapidly, and the rules for safe handling, prescribing, and dispensing are not the same everywhere.

How GH Physiology Differs in Women

Women secrete more GH per 24 hours than men throughout reproductive life, driven partly by estrogen's direct effect on pituitary somatotrophs. IGF-1 responses differ too: the same GH dose produces a lower IGF-1 rise in estrogen-replete women than in men, a pharmacokinetic reality that matters when clinicians interpret lab values or set targets.

After menopause, estrogen falls, and so does GH pulse amplitude. Post-menopausal women on oral estrogen therapy show further blunted IGF-1 responses compared to those using transdermal estrogen, because oral estrogen undergoes first-pass hepatic metabolism and upregulates GH resistance at the liver. This is not an academic footnote. If you are using oral HRT and a clinician is monitoring your IGF-1 on a GHRH analog, the target range used in the Egrifta SV trials may not apply directly to you.

Conditions in Women Where the GH Axis Is Clinically Relevant

The GH axis touches several conditions that disproportionately affect women:

• PCOS. Women with PCOS often have altered GH pulsatility and elevated IGF-1 relative to controls, which amplifies androgen production in the ovarian theca cells. Adding a GHRH analog in PCOS without careful IGF-1 monitoring is poorly studied and carries theoretical risk.
• Perimenopause and menopause. Declining GH contributes to the shift in body composition (visceral fat gain, lean mass loss) that many women notice in their late 40s. The GH axis is one mechanistic target being explored, though no GHRH analog is approved for menopausal body composition.
• Osteoporosis. GH and IGF-1 support bone remodeling. Women lose bone faster in the years around menopause. Whether GH-axis stimulation offers additive benefit alongside standard anti-resorptive therapy remains an open research question.
• Female pattern hair loss and hormonal acne. Both have been anecdotally linked to GH-axis changes. Evidence for GHRH analogs as treatment is essentially absent in women-specific trials.

Do GHRH Analogs Have an Active REMS Program?

No GHRH analog currently carries a formal FDA Risk Evaluation and Mitigation Strategy. This is a fact worth understanding clearly, because the absence of a REMS does not mean the absence of regulatory oversight.

The FDA REMS database lists programs for drugs where the FDA has determined that standard labeling alone is insufficient to manage a serious risk. Tesamorelin (Egrifta SV), the only currently FDA-approved GHRH analog in the United States, does not appear there. Sermorelin's original NDA (NDA 19-832) was voluntarily withdrawn by the manufacturer in 2008, so it no longer has an active approved product, and therefore has no REMS framework.

Why the Absence of REMS Does Not Mean Absence of Risk Controls

Several overlapping systems still govern how GHRH analogs reach patients:

FDA approval status and off-label use. Tesamorelin is approved only for HIV-associated lipodystrophy in adults. Prescribing it for menopause-related body composition changes or athletic recovery is off-label. The FDA's guidance on off-label prescribing does not prohibit this, but it shifts risk-management responsibility to the prescriber and requires documented informed consent in most institutional settings.

Compounding regulations. The vast majority of sermorelin dispensed today comes from compounding pharmacies. The FDA placed sermorelin on its Category 2 list of bulk drug substances, which means 503B outsourcing facilities may not compound it without specific authorization. Individual 503A pharmacies face a patchwork of state board regulations. This is an area where rules changed meaningfully between 2023 and 2025, and patients should confirm current status with their pharmacy before starting.

USP standards. Compounded sterile preparations, including injectable sermorelin, must meet USP <797> sterility and stability standards. Failures in this area are not hypothetical: contaminated compounded sterile injectables have caused serious infections in the past.

Special Handling Requirements for Compounded GHRH Peptides

Storage, Reconstitution, and Stability

Lyophilized (freeze-dried) sermorelin powder must be refrigerated at 2 to 8 degrees Celsius before reconstitution. Once you add bacteriostatic water, the reconstituted solution is typically stable for 30 days refrigerated, though specific beyond-use dates depend on the compounding pharmacy's stability testing data. Room-temperature excursions degrade the peptide faster than most patients assume.

A few practical points that matter specifically if you are a woman using sermorelin subcutaneously at home:

• Injection sites should be rotated across the lower abdomen, thighs, and outer upper arm. Abdominal adipose distribution differs between pre-menopausal and post-menopausal women, which can affect subcutaneous absorption variability.
• Sermorelin is typically injected at bedtime to align with the physiologic nocturnal GH surge. Missing doses or injecting at variable times disrupts this pattern more in women, because female GH pulsatility is already more variable across the menstrual cycle.
• Needles and syringes are considered sharps. Your state or municipality has specific sharps disposal rules. A list of mail-back and drop-off programs is available through the FDA safe sharps disposal guidance.

Injection Technique and Monitoring in Women

Because estrogen status changes how IGF-1 responds to GH stimulation, monitoring is not one-size-fits-all. A woman in her late reproductive years on combined oral contraceptives has a different IGF-1 baseline than a woman of the same age who is post-menopausal on transdermal estradiol, and both differ from a woman who is unmedicated.

The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults recommends targeting IGF-1 in the mid-normal range for age and sex, not the upper quartile. Clinicians treating women off-label with GHRH analogs should use the same principle, adjusted for estrogen status.

Pregnancy and Lactation Safety: A Required Conversation

Pregnancy: Contraindicated. There are no adequate, well-controlled studies of sermorelin or tesamorelin in pregnant women. Animal reproduction studies of tesamorelin showed embryotoxicity at doses producing exposures lower than the human clinical dose. The Egrifta SV prescribing information carries a clear contraindication in pregnancy.

If you could become pregnant, you need effective contraception before starting any GHRH analog. The teratogenic risk profile is not as well-characterized as, say, isotretinoin or thalidomide, but the absence of safety data in human pregnancies is itself a reason for caution. Stop the drug at least one full treatment cycle before attempting conception; discuss the timeline with your prescriber.

Trying to conceive. The GH axis influences ovarian folliculogenesis. IGF-1 produced locally in the ovary amplifies FSH signaling, and some small studies have explored GH co-treatment in poor responders undergoing IVF. A 2019 Cochrane review of GH supplementation in poor responders found a possible benefit in live birth rates, but evidence quality was low and the review covered exogenous GH, not GHRH analogs. Using GHRH analogs to enhance fertility is not standard of care and is not recommended outside a monitored research or fertility clinic context.

Lactation. It is unknown whether sermorelin or tesamorelin transfers into human breast milk. The molecular weight of tesamorelin (around 5,100 daltons) suggests limited passive transfer, but data are absent. Given the lack of evidence and the theoretical effect of supraphysiologic GH axis stimulation on a nursing infant's growth signaling, clinicians should recommend avoiding GHRH analogs during breastfeeding.

Postpartum. GH pulsatility is suppressed during late pregnancy and recovers gradually postpartum, more slowly in women who breastfeed. This is a physiologic state, not a deficiency. There is no evidence supporting the use of GHRH analogs in the postpartum period.

Who Is a Candidate and Who Is Not: A Life-Stage View

This framework is not taken from any single guideline. It synthesizes the Egrifta SV prescribing information, Endocrine Society GHD guidance, and the sex-specific GH physiology literature to create a practical, life-stage view for women's clinicians.

Women Who May Be Appropriate Candidates

| Life Stage | Potential Clinical Context | Notes | |---|---|---| | Reproductive years (18-40) | Documented GH deficiency (pituitary pathology, cranial radiation) | IGF-1 targets must account for OCP use | | Perimenopause (40-52) | Off-label: visceral adiposity, fatigue with low IGF-1 | No approved indication; informed consent required | | Post-menopause | HIV lipodystrophy (tesamorelin, on-label) | Adjust IGF-1 target for estrogen status | | Post-menopause | Off-label: body composition, bone health research context | Evidence base is thin; see evidence gap note below |

Women Who Are Not Candidates

• Active or suspected malignancy. GH and IGF-1 are mitogenic. The Endocrine Society guideline lists active malignancy as an absolute contraindication to GH-axis stimulation.
• Pregnancy or breastfeeding (see above).
• Uncontrolled diabetes. GH is counter-regulatory to insulin. Tesamorelin was shown in the LIPO-010 trial to increase fasting glucose and HbA1c in some patients. Women with PCOS who already have insulin resistance need careful glucose monitoring before and during treatment.
• Proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy, as noted in the Egrifta SV label.
• Pituitary tumor or recent pituitary surgery without confirmed adequate tissue for GHRH-stimulated response.

The Evidence Gap: What We Know and Do Not Know in Women

Women have been systematically under-represented in growth hormone and GHRH analog trials. The key tesamorelin trials, LIPO-010 and LIPO-011, enrolled populations that were approximately 85 percent male, reflecting the HIV-positive population at the time. Subgroup analyses in women were not powered to detect sex-specific differences in efficacy or adverse events.

This is a meaningful evidence gap. Women's GH-axis physiology differs from men's in ways that are not minor adjustments. Extrapolating dose-response curves and IGF-1 targets from predominantly male trial populations to women of varying estrogen status involves real clinical uncertainty. When your clinician says a dose is "standard," ask whether that standard was derived from a population that looks like you.

The NIH Office of Research on Women's Health has called explicitly for sex-disaggregated reporting in endocrine trials, and this class is one where that call has gone largely unheeded.

Prescribing Pathway and What to Expect at Your Pharmacy

Because no branded sermorelin product is currently marketed in the United States, a prescription for sermorelin almost always goes to a compounding pharmacy. Here is what the pathway typically looks like:

1. Your provider orders a baseline IGF-1, fasting glucose, HbA1c, and (in perimenopausal and post-menopausal women) estradiol level.
2. The prescription is sent to a licensed 503A compounding pharmacy in your state, or to a 503B outsourcing facility if the dose is non-patient-specific.
3. The pharmacy prepares lyophilized sermorelin, typically 2 mg or 5 mg vials, under USP <797> sterile compounding standards.
4. You self-inject subcutaneously, usually 100 to 300 mcg nightly. Note: these dose ranges come from clinical practice patterns and the original NDA data, not from a current FDA-approved label, because that label no longer exists.
5. IGF-1 is rechecked at 6 to 8 weeks and the dose is titrated to keep IGF-1 in the mid-normal range for your age and sex.

Tesamorelin (Egrifta SV) follows a conventional pharmacy dispensing pathway as an approved product. It is supplied as 2 mg vials for reconstitution, injected subcutaneously once daily into the abdomen. The approved dose is 2 mg once daily. Insurance coverage outside the HIV lipodystrophy indication is essentially unavailable.

Interactions That Matter in Women

Several drug interactions are specifically relevant to the conditions women commonly manage:

• Oral estrogens. As noted above, oral estrogens blunt hepatic IGF-1 production. If you switch from oral to transdermal estradiol while on a GHRH analog, your IGF-1 may rise without any dose change, requiring a monitoring recheck.
• Glucocorticoids. Chronic corticosteroid use (sometimes prescribed for autoimmune conditions more common in women, such as lupus or rheumatoid arthritis) impairs the pituitary GH response to GHRH. A GHRH analog may be less effective, and the dose may need upward adjustment.
• Thyroid hormone. Hypothyroidism, which affects women at roughly 5 to 8 times the rate of men, blunts GH secretion. Adequate thyroid replacement is a prerequisite for meaningful GHRH-analog response. Untreated or under-treated hypothyroidism is one reason a woman might appear to be a "non-responder."
• Insulin and oral hypoglycemics. Because GHRH analogs raise GH, which is counter-regulatory to insulin, glucose-lowering medication doses may need adjustment. Women with PCOS on metformin should have fasting glucose rechecked within 4 to 6 weeks of starting.

Adverse Effects With a Women's-Health Lens

The most common adverse effects reported in the Egrifta SV trials (injection site reactions, edema, arthralgia, myalgia, and paresthesias) are similar across sexes. A few effects are worth flagging specifically for women:

• Fluid retention. GH promotes sodium and water retention. This can worsen in the luteal phase of the menstrual cycle, when progesterone already causes some fluid shifts. Women who notice cyclical worsening of edema should track symptoms in relation to their cycle.
• Glucose intolerance. In the LIPO-010 trial, 4.4 percent of tesamorelin-treated patients developed diabetes mellitus versus 1.1 percent in the placebo group. Women with PCOS, who already carry elevated diabetes risk, need extra vigilance.
• Cortisol and thyroid screening. The pituitary makes more than GH. Rarely, a pituitary adenoma presenting as secondary GH deficiency can also affect cortisol and thyroid output. Screening TSH and morning cortisol before starting is standard in any woman whose GH deficiency lacks a clear cause.

A Note on Telehealth Prescribing and Verification

GHRH analog prescriptions through telehealth platforms are legal in most US states, but your provider has specific obligations: a valid prescriber-patient relationship, documented indication and risk discussion, and state-specific rules on prescribing compounded injectables via telemedicine. The DEA's 2023 proposed telemedicine rules affect controlled substances more than peptides, but state medical boards have their own standards.

Ask your telehealth provider to document in your chart: the clinical rationale, your baseline IGF-1 value, the specific compounding pharmacy being used, and the monitoring plan. This protects you and establishes the medical necessity record if questions arise later.